Navigation Links
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
Date:2/25/2009

tables titled "Reconciliation of GAAP Net Loss to Non-GAAP Net Loss" for a description of these non-GAAP financial measures, including reasons for Medarex management's decision to use each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles.

Conference Call and Webcast Details

Medarex will hold a public conference call and webcast today, February 25, 2009, at 4:30 p.m. Eastern Time to review its financial and business results. To access the call live, please dial 1-866-804-6925 (U.S./Canada) or 1-857-350-1671 (international) and enter passcode number 405-36-543. The webcast can be accessed through the Investor Relations section of Medarex's website at www.medarex.com and will be archived for 7 days following the webcast. A telephonic replay of the conference call will be available following the event until midnight Eastern Time, March 5, 2009. Access numbers for this replay are 1-888-286-8010 (U.S./Canada) or 1-617-801-6888 (international); passcode number 263-79-360.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. Medarex Reviews Recent Highlights and Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 The ... program is this Friday, June 21 at midnight ... ongoing programs and innovative people who’ve raised the ... information, visit http://www.minonline.com/ima . , Any consumer ... magazine title is eligible to enter. Additionally, advertising ...
(Date:6/19/2013)... Utah (PRWEB) June 19, 2013 Today, ... Wisconsin Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, as part of the Affordable ... small businesses will become available through new state health ...
(Date:6/19/2013)... The Journal of Parasitology – Although ... software, it creates questions of ethics. For scientific publications, ... already published case shows, scientific publications need clear guidelines ... Journal of Parasitology features a commentary on ... article published in the Journal of the New York ...
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... early April, senior leaders from medical, law enforcement, military, ... one question: how can first responders improve survival after ... results of this discussion are now available in " ... ," a concept paper published in the June issue ... Acute Care Surgery , official publication of the ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... are supporting WaterAid to deliver the most wished for Christmas present in ... ... Bendalls are appealing to social media groups, the Australian blog community and ... donate and download a e-Christmas Card , with a personalized message. ...
... scientists and the news media have evolved tremendously over ... improve communications with both the media and the lay ... commentary appears this month in a major scientific journal. ... and pharmacology at Wake Forest University School of Medicine, ...
... white women to have reconstruction after mastectomy , , MONDAY, ... women are more likely to have immediate breast reconstruction ... , This is also true for more educated women ... black women and those who live in predominantly black ...
... found little link between drinking and malignancies , , MONDAY, ... your chances of developing cancer after age 65, new ... lack of physical activity were among the usual suspects ... to the Duke University study. , The findings are ...
... nanoparticles and polymer carriers as potential new techniques ... and blindness in the United States, according to ... Research Institute Conference. , The report ( http://www.iovs.org/cgi/content/full/49/11/4712 ... for ocular drug delivery to the posterior segment ...
... LAKE CITY Nov. 17, 2008 Researchers at the ... trial that uses a patient,s own stem cells to treat ... Repair Cell Treatment of Patients with Dilated Cardiomyopathy (IMPACT-DCM) study ... (CRC) and their ability to improve heart function. , Patients ...
Cached Medicine News:Health News:Urgent Request for Water 2Health News:Award-winning researcher says relationships with news media, public are critical 2Health News:Award-winning researcher says relationships with news media, public are critical 3Health News:Wealthy More Likely to Have Breast Reconstruction 2Health News:Stay Upbeat, Exercise to Help Prevent Cancer in Old Age 2Health News:Conference report highlights new research into drug delivery to treat eye disease 2Health News:U of U researchers to use patient's own stem cells to treat heart failure 2
(Date:6/19/2013)... SUNNYVALE, Calif. , June 19, 2013 ... today announced that The New England Journal of ... a Phase 1b/2 study evaluating the investigational oral Bruton,s ... chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ... patients with relapsed/refractory CLL or SLL, even in patients ...
(Date:6/19/2013)... CHICAGO , June 19, 2013 The Physician-Patient ... reduce alarm fatigue. The need to urgently address ... in its Sentinel Event Alert #50 , "Medical device alarm ... Alert database, between January 2008 and June 2012, there were ... 80 resulted in death (82%) , 13 resulted in ...
(Date:6/19/2013)...   Voices Against Brain Cancer (VABC), a ... cancer, today announced that it has awarded Tocagen Inc. ... investigation of Toca 511 & Toca FC in patients ... (Grade 3 or Grade 4).  Tocagen is a privately ... with an initial focus on brain cancer. ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
Post-Surgical compression garments...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
... menu includes kits that quantitatively measure two ... (a). An elevated serum or plasma homocysteine ... and independent risk factor for cardiovascular disease. ... have associated elevated levels of Lp(a) with ...
Medicine Products: